Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,673	$ 1,718
Accounts receivable, net of allowances of $122 in 2023 and $114 in 2022	2,547	2,659
Inventories	2,922	2,718
Prepaid expenses and other current assets	957	916
Total current assets	8,099	8,011
Property, plant and equipment, net	5,000	4,979
Goodwill	6,868	6,843
Other intangible assets, net	6,640	6,793
Operating lease right-of-use assets	554	550
Other non-current assets	1,130	1,111
Total assets	28,291	28,287
Current liabilities:
Short-term debt	50	299
Current maturities of long-term debt and finance lease obligations	1,103	1,105
Accounts payable	1,290	1,139
Accrued expenses and other current liabilities	2,317	2,202
Total current liabilities	4,760	4,745
Long-term debt and finance lease obligations, less current portion	15,278	15,232
Operating lease liabilities	458	456
Other non-current liabilities	1,854	1,959
Total liabilities	22,350	22,392
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2023 and 2022	683	683
Common stock in treasury, at cost,177,658,649 shares in 2023 and 179,062,594 shares in 2022	(11,324)	(11,389)
Additional contributed capital	6,312	6,322
Retained earnings	13,947	14,050
Accumulated other comprehensive income (loss)	(3,739)	(3,833)
Total Baxter stockholders’ equity	5,879	5,833
Noncontrolling interests	62	62
Total equity	5,941	5,895
Total liabilities and equity	$ 28,291	$ 28,287